全文获取类型
| 收费全文 | 192篇 |
| 免费 | 3篇 |
| 国内免费 | 3篇 |
专业分类
| 林业 | 2篇 |
| 农学 | 1篇 |
| 综合类 | 143篇 |
| 农作物 | 2篇 |
| 畜牧兽医 | 43篇 |
| 园艺 | 4篇 |
| 植物保护 | 3篇 |
出版年
| 2023年 | 4篇 |
| 2022年 | 1篇 |
| 2021年 | 2篇 |
| 2020年 | 1篇 |
| 2019年 | 2篇 |
| 2017年 | 4篇 |
| 2016年 | 3篇 |
| 2015年 | 10篇 |
| 2014年 | 17篇 |
| 2013年 | 25篇 |
| 2012年 | 22篇 |
| 2011年 | 48篇 |
| 2010年 | 19篇 |
| 2009年 | 10篇 |
| 2008年 | 6篇 |
| 2007年 | 6篇 |
| 2006年 | 2篇 |
| 2005年 | 4篇 |
| 2004年 | 3篇 |
| 2002年 | 2篇 |
| 2001年 | 1篇 |
| 2000年 | 1篇 |
| 1999年 | 1篇 |
| 1994年 | 1篇 |
| 1983年 | 1篇 |
| 1978年 | 1篇 |
| 1977年 | 1篇 |
排序方式： 共有198条查询结果，搜索用时 265 毫秒
1.
奶牛乳腺炎防治的免疫学和药理学机制 总被引：8，自引：0，他引：8
奶牛乳腺炎是一种复杂的多因素疾病，给世界各国奶牛业造成了巨大的经济损失，而至今未能提出一个彻底解决的办法。本文综述了奶牛乳腺炎的致病因素、乳腺的免疫机制和乳腺炎治疗的药理学机制方面的研究进展，重点剖析了乳腺特殊的免疫体系和乳腺炎治疗的药理学特点，分析阐明了奶牛乳腺炎免疫和治疗失败的原因。 相似文献
2.
3.
茶黄素类抗肿瘤作用研究进展 总被引：3，自引：0，他引：3
简述了茶黄素类(Theaflavins，TFs)的化学结构，并从抗肿瘤、抗炎、抗氧化、抗病毒和抗心血管疾病五个方面综述了茶黄素类的药理作用，其中从肿瘤的发生、发展两个阶段着重分析了茶黄素类的作用机理，最后提出了TFs作为药品开发所存在的问题。 相似文献
4.
5.
6.
G.W. Smith J.L. Davis S.M. Smith M.P. Gerard N.B. Campbell D.M. Foster 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2010,24(4):949-955
Background: Despite frequent clinical use, information about the pharmacokinetics and efficacy of pantoprazole in camelids is not available. Objectives: To examine the pharmacokinetics of both IV and SC pantoprazole and to determine whether pantoprazole administration would increase 3rd compartment pH in alpacas. Animals: Six healthy adult alpacas. Methods: Alpacas were fitted with a 3rd compartment cannula for measuring gastric pH. After recovery, alpacas received 1 mg/kg pantoprazole IV, q24h for 3 days or 2 mg/kg SC q24h for 3 days. Alpacas received both IV and SC pantoprazole, with a minimum of 3 weeks between treatments. Third compartment pH was recorded and plasma samples were taken for pharmacokinetic analysis. Results: Pantoprazole induced a slow but sustained increase in 3rd compartment pH when given by both the IV and SC routes. Third compartment pH was significantly increased as compared with baseline values (1.81 ± 0.7; mean ± SD) at 24 (2.47 ± 0.8), 48 (3.53 ± 1.0) and 72 hours (4.03 ± 1.3) after daily IV administration of pantoprazole. Third compartment pH increased from 1.73 ± 0.6 at baseline to 3.05 ± 1.1, 4.02 ± 1.4, and 3.61 ± 1.6 at 24, 48, and 72 hours after SC administration, respectively. Pharmacokinetic analysis demonstrated that pantoprazole had a short elimination half‐life (0.47 + 0.06 h) and a high clearance rate (12.2 ± 2.9 mL/kg/min) after both IV and SC administration. Conclusions and Clinical Relevance: Based on the results of this study, pantoprazole represents a safe and effective drug for increasing 3rd compartment pH in camelids. Either IV or SC administration is likely to be an effective treatment for gastric ulcers. 相似文献
7.
C. Khanna M. Rosenberg D. M. Vail 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2015,29(4):1006-1012
Paclitaxel is a commonly used chemotherapeutic agent with a broad spectrum of activity against cancers in humans. In 1992, paclitaxel was approved by the U.S. Food and Drug Administration (FDA) as Taxol® for use in advanced ovarian cancer. Two years later, it was approved for the treatment of metastatic breast cancer. Paclitaxel was originally isolated from the bark of the Pacific yew tree, Taxus brevifolia in 1971. Taxanes are a family of microtubule inhibitors. As a member of this family, paclitaxel suppresses spindle microtubule dynamics. This activity results in the blockage of the metaphase‐anaphase transitions, and ultimately in the inhibition of mitosis, and induction of apoptosis in a wide spectrum of cancer cells. Additional anticancer activities of paclitaxel have been defined that are independent of these effects on the microtubules and may include the suppression of cell proliferation as well as antiangiogenic effects. Based on its targeting of a fundamental feature of the cancer phenotype, the mitotic complex, it is not surprising that paclitaxel has been found to be active in a wide variety of cancers in humans. This review summarizes the evidence in support of paclitaxel's broad anticancer activity and introduces the rationale for, and the progress in development of novel formulations of paclitaxel that may preferentially target cancers and that are not associated with the risks for hypersensitivity in dogs. Of note, a novel nanoparticle formulation of paclitaxel that substantially limits hypersensitivity was recently given conditional approval by the FDA Center for Veterinary Medicine for use in dogs with resectable and nonresectable squamous cell carcinoma and nonresectable stage III, IV and V mammary carcinoma. 相似文献
8.
9.
10.